Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan

Background: Methotrexate is the first-line drug for treating patients with juvenile idiopathic arthritis (JIA). If it is ineffective or intolerable, prescription of genetically engineered biopharmaceuticals is indicated. Objective: The study was aimed at assessing effectiveness and safety of genetic...

Full description

Bibliographic Details

Published in:	Педиатрическая фармакология
Main Authors:	V. A. Maliyevskiy, O. A. Maliyevskiy, G. R. Gareyeva, L. S. Nazarova, A. A. Khasanova, A. Z. Nuriyakhmetova, D. D. Prolygina
Format:	Article
Language:	Russian
Published:	Union of pediatricians of Russia 2016-02-01
Subjects:	children juvenile idiopathic arthritis genetically engineered biopharmaceuticals adalimumab
Online Access:	https://www.pedpharma.ru/jour/article/view/1367